During Friday's early trading session, genome analysis scientific instrument company Bionano Genomics (BNGO) raised its 2025 optical genome mapping (OGM) equipment installation target to 25 units, while consumables and software revenue increased by 16%. The company reported second quarter revenue of $6.7 million and is currently focusing on supporting routine users of its optical genome mapping technology.
Bionano is driving business growth by strengthening its software product portfolio.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.